← All tool previews

Tool Preview

Lab Visualizer

This is a preview of the cooperative's tools, built with sample data for a fictional patient. The production platform will be adapted from open-source infrastructure. Lab values shown here are realistic but not from a real person.

Viewing labs for: Sample Member

Diagnosis Multiple myeloma, IgG kappa

Diagnosed January 2026, age 38

Current Status Maintenance therapy (lenalidomide)

Data Source Patient-directed collection via FHIR

Serum M-Protein

Tracks the abnormal protein produced by myeloma cells. A declining trend during treatment signals a response. Reference range for normal: below 0.3 g/dL.

M-Protein (g/dL) Normal reference range

Free Light Chains

Kappa and lambda light chains help monitor myeloma activity. The ratio between them is often the most sensitive marker. Normal kappa: 3.3 to 19.4 mg/L. Normal lambda: 5.7 to 26.3 mg/L.

Kappa (mg/L) Lambda (mg/L)

Kappa/Lambda Ratio

The ratio between kappa and lambda free light chains. A normalizing ratio is a strong indicator of treatment response. Normal range: 0.26 to 1.65.

Kappa/Lambda Ratio Normal reference range

Hemoglobin

Measures oxygen-carrying capacity. Myeloma and chemotherapy often lower hemoglobin. Recovery during maintenance is a positive sign. Normal range: 13.5 to 17.5 g/dL.

Hemoglobin (g/dL) Normal reference range

White Blood Cells (WBC)

Tracks immune system capacity. Treatment cycles and transplant cause expected dips. Normal range: 4.5 to 11.0 × 10³/μL.

WBC (× 10³/μL) Normal reference range

Platelets

Essential for blood clotting. Chemotherapy temporarily reduces platelet counts. Recovery is expected during maintenance. Normal range: 150 to 400 × 10³/μL.

Platelets (× 10³/μL) Normal reference range

M-Protein (g/dL)

Kappa FLC (mg/L)

Kappa/Lambda Ratio

Hemoglobin (g/dL)

WBC (× 10³/μL)

Platelets (× 10³/μL)

Treatment Timeline

VRd Induction
ASCT
Lenalidomide Maintenance
VRd: bortezomib, lenalidomide, dexamethasone (Jan–Jun 2026) Autologous stem cell transplant (Jul–Aug 2026) Lenalidomide maintenance (Sep 2026–present)

Your labs, your view.

As a founding member, you'll connect your own lab results through our secure platform. You control what's shared, with whom, and for how long.

Become a founding member